Pfizer breast cancer prospect grabs FDA's speedy review promise

Pfizer's ($PFE) pipeline could use a big approval, and it may have one coming in palbociclib. The pharma giant has nabbed an FDA priority review designation for the closely watched cancer drug, which could potentially hack four months off the review timeline. Assuming approval, analysts see peak sales in the $3 billion range in Pfizer's future. More from FierceBiotech

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.